I am a
Home I AM A Search Login

Papers of the Week

Papers: 5 Feb 2022 - 11 Feb 2022

Human Studies, Pharmacology/Drug Development

2022 Feb 07

J Headache Pain



Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study.


McAllister P, Winner PK, Ailani J, Buse DC, Lipton RB, Chakhava G, Josiassen M K, Lindsten A, Mehta L, Ettrup A, Cady R
J Headache Pain. 2022 Feb 07; 23(1):22.
PMID: 35130832.


Demonstrating therapeutic value from the patient perspective is important in patient-centered migraine management. The objective of this study was to investigate the impact of eptinezumab, a preventive migraine treatment, on patient-reported headache impact, acute medication optimization, and perception of disease change when initiated during a migraine attack.